NEW YORK, NY--(Marketwire - July 18, 2012) -
Daxor Corporation (NYSE MKT: DXR
), an investment company with medical instrumentation and biotechnology operations, today announced the placement of Daxor's BVA-100 Blood Volume Analyzer at New York Presbyterian/Weill Cornell Medical Center.
Tracing their roots back to 1771, the New York Presbyterian/Weill Cornell Medical Center is one of the most acclaimed healthcare institutions in history. New York Presbyterian is a Level I Trauma Center for pediatric and adult patients, as well as a Stroke, Hyperbaric, PCI and Burn Center. Based in New York City, they are the nation's largest not-for-profit, non-sectarian hospital, with 2,409 beds. The Hospital has nearly 2 million inpatient and outpatient visits in a year, including 12,797 deliveries and 195,294 visits to its emergency departments. NewYork-Presbyterian's 6,144 affiliated physicians and 19,376 staff provide state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine at five major centers: The Allen Hospital, Morgan Stanley Children's Hospital of New York-Presbyterian, New York-Presbyterian Hospital/Columbia University Medical Center, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York-Presbyterian Hospital/Westchester Division.
New York Presbyterian has just been ranked #7 in the 2012 U.S. News and World Report for Best Hospitals in the entire United States and #1 in the New York/New Jersey region.
James A. Osorio, MD, Assistant Professor of Anesthesiology and Critical Care Fellowship Program Director Critical Care Medicine, said, "We are looking forward to bringing blood volume analysis to our hospital. We see it fit for fluid management of our patients in the Cardiothoracic, Burn and Surgery/Trauma ICU."
Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.